A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis

Donato Greco, Stefania Salmaso, Paola Mastrantonio, Marina Giuliano, Alberto E. Tozzi, Alessandra Anemona, Marta L. Ciofi Degli Atti, Anna Giammanco, Pietro Panei, Willlam C. Blackwelder, David L. Klein, Steven G F Wassilak

Research output: Contribution to journalArticle

563 Citations (Scopus)

Abstract

Background. Concern about both safety and efficacy has made the use of whole-cell pertussis vaccines controversial. In some European countries, including Italy, the rate of vaccination against pertussis is low. Methods. We conducted a double-blind trial in Italy in which infants were randomly assigned to vaccination at two, four, and six months of age with an acellular pertussis vaccine together with diphtheria and tetanus toxoids (DTP); a DTP vaccine containing whole-cell pertussis (manufactured by Connaught Laboratories); or diphtheria and tetanus toxoids without pertussis (DT). The acellular DTP vaccine was either one containing filamentous hemagglutinin, pertactin, and pertussis toxin inactivated with formalin and glutaraldehyde (SmithKline Beecham) or one with filamentous hemagglutinin, pertactin, and genetically detoxified pertussis toxin (Chiron Biocine). Pertussis was defined as 21 days or more of paroxysmal cough, with infection confirmed by culture or serologic testing. Results. The efficacy of each vaccine, given in three doses, against pertussis was determined for 14,751 children over an average of 17 months, with cases included in the analysis if cough began 30 days or more after the completion of immunization. For both of the acellular DTP vaccines, the efficacy was 84 percent (95 percent confidence intervals, 76 to 89 percent for SmithKline DTP and 76 to 90 percent for Biocine DTP), whereas the efficacy of the whole-cell DTP vaccine was only 36 percent (95 percent confidence interval, 14 to 52 percent). The antibody responses were greater to the acellular vaccines than to the whole-cell vaccine. Local and systemic adverse events were significantly more frequent after the administration of the whole-cell vaccine. For the acellular vaccines, the frequency of adverse events was similar to that in the control (DT) group. Conclusions. The two acellular DTP vaccines we studied were safe, immunogenic, and efficacious against pertussis, whereas the efficacy of the whole-cell DTP vaccine was unexpectedly low.

Original languageEnglish
Pages (from-to)341-348
Number of pages8
JournalNew England Journal of Medicine
Volume334
Issue number6
DOIs
Publication statusPublished - Feb 8 1996

Fingerprint

Diphtheria-Tetanus-Pertussis Vaccine
Acellular Vaccines
Pertussis Vaccine
Whooping Cough
Diphtheria Toxoid
Tetanus Toxoid
Vaccines
Pertussis Toxin
Hemagglutinins
Cough
Italy
Vaccination
Confidence Intervals
Glutaral
Formaldehyde
Antibody Formation
Immunization
Safety
Control Groups
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi, A. E., Anemona, A., ... Wassilak, S. G. F. (1996). A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. New England Journal of Medicine, 334(6), 341-348. https://doi.org/10.1056/NEJM199602083340601

A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. / Greco, Donato; Salmaso, Stefania; Mastrantonio, Paola; Giuliano, Marina; Tozzi, Alberto E.; Anemona, Alessandra; Ciofi Degli Atti, Marta L.; Giammanco, Anna; Panei, Pietro; Blackwelder, Willlam C.; Klein, David L.; Wassilak, Steven G F.

In: New England Journal of Medicine, Vol. 334, No. 6, 08.02.1996, p. 341-348.

Research output: Contribution to journalArticle

Greco, D, Salmaso, S, Mastrantonio, P, Giuliano, M, Tozzi, AE, Anemona, A, Ciofi Degli Atti, ML, Giammanco, A, Panei, P, Blackwelder, WC, Klein, DL & Wassilak, SGF 1996, 'A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis', New England Journal of Medicine, vol. 334, no. 6, pp. 341-348. https://doi.org/10.1056/NEJM199602083340601
Greco, Donato ; Salmaso, Stefania ; Mastrantonio, Paola ; Giuliano, Marina ; Tozzi, Alberto E. ; Anemona, Alessandra ; Ciofi Degli Atti, Marta L. ; Giammanco, Anna ; Panei, Pietro ; Blackwelder, Willlam C. ; Klein, David L. ; Wassilak, Steven G F. / A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. In: New England Journal of Medicine. 1996 ; Vol. 334, No. 6. pp. 341-348.
@article{932c53a4656b4a7faa5ffe313fcf7d7a,
title = "A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis",
abstract = "Background. Concern about both safety and efficacy has made the use of whole-cell pertussis vaccines controversial. In some European countries, including Italy, the rate of vaccination against pertussis is low. Methods. We conducted a double-blind trial in Italy in which infants were randomly assigned to vaccination at two, four, and six months of age with an acellular pertussis vaccine together with diphtheria and tetanus toxoids (DTP); a DTP vaccine containing whole-cell pertussis (manufactured by Connaught Laboratories); or diphtheria and tetanus toxoids without pertussis (DT). The acellular DTP vaccine was either one containing filamentous hemagglutinin, pertactin, and pertussis toxin inactivated with formalin and glutaraldehyde (SmithKline Beecham) or one with filamentous hemagglutinin, pertactin, and genetically detoxified pertussis toxin (Chiron Biocine). Pertussis was defined as 21 days or more of paroxysmal cough, with infection confirmed by culture or serologic testing. Results. The efficacy of each vaccine, given in three doses, against pertussis was determined for 14,751 children over an average of 17 months, with cases included in the analysis if cough began 30 days or more after the completion of immunization. For both of the acellular DTP vaccines, the efficacy was 84 percent (95 percent confidence intervals, 76 to 89 percent for SmithKline DTP and 76 to 90 percent for Biocine DTP), whereas the efficacy of the whole-cell DTP vaccine was only 36 percent (95 percent confidence interval, 14 to 52 percent). The antibody responses were greater to the acellular vaccines than to the whole-cell vaccine. Local and systemic adverse events were significantly more frequent after the administration of the whole-cell vaccine. For the acellular vaccines, the frequency of adverse events was similar to that in the control (DT) group. Conclusions. The two acellular DTP vaccines we studied were safe, immunogenic, and efficacious against pertussis, whereas the efficacy of the whole-cell DTP vaccine was unexpectedly low.",
author = "Donato Greco and Stefania Salmaso and Paola Mastrantonio and Marina Giuliano and Tozzi, {Alberto E.} and Alessandra Anemona and {Ciofi Degli Atti}, {Marta L.} and Anna Giammanco and Pietro Panei and Blackwelder, {Willlam C.} and Klein, {David L.} and Wassilak, {Steven G F}",
year = "1996",
month = "2",
day = "8",
doi = "10.1056/NEJM199602083340601",
language = "English",
volume = "334",
pages = "341--348",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "6",

}

TY - JOUR

T1 - A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis

AU - Greco, Donato

AU - Salmaso, Stefania

AU - Mastrantonio, Paola

AU - Giuliano, Marina

AU - Tozzi, Alberto E.

AU - Anemona, Alessandra

AU - Ciofi Degli Atti, Marta L.

AU - Giammanco, Anna

AU - Panei, Pietro

AU - Blackwelder, Willlam C.

AU - Klein, David L.

AU - Wassilak, Steven G F

PY - 1996/2/8

Y1 - 1996/2/8

N2 - Background. Concern about both safety and efficacy has made the use of whole-cell pertussis vaccines controversial. In some European countries, including Italy, the rate of vaccination against pertussis is low. Methods. We conducted a double-blind trial in Italy in which infants were randomly assigned to vaccination at two, four, and six months of age with an acellular pertussis vaccine together with diphtheria and tetanus toxoids (DTP); a DTP vaccine containing whole-cell pertussis (manufactured by Connaught Laboratories); or diphtheria and tetanus toxoids without pertussis (DT). The acellular DTP vaccine was either one containing filamentous hemagglutinin, pertactin, and pertussis toxin inactivated with formalin and glutaraldehyde (SmithKline Beecham) or one with filamentous hemagglutinin, pertactin, and genetically detoxified pertussis toxin (Chiron Biocine). Pertussis was defined as 21 days or more of paroxysmal cough, with infection confirmed by culture or serologic testing. Results. The efficacy of each vaccine, given in three doses, against pertussis was determined for 14,751 children over an average of 17 months, with cases included in the analysis if cough began 30 days or more after the completion of immunization. For both of the acellular DTP vaccines, the efficacy was 84 percent (95 percent confidence intervals, 76 to 89 percent for SmithKline DTP and 76 to 90 percent for Biocine DTP), whereas the efficacy of the whole-cell DTP vaccine was only 36 percent (95 percent confidence interval, 14 to 52 percent). The antibody responses were greater to the acellular vaccines than to the whole-cell vaccine. Local and systemic adverse events were significantly more frequent after the administration of the whole-cell vaccine. For the acellular vaccines, the frequency of adverse events was similar to that in the control (DT) group. Conclusions. The two acellular DTP vaccines we studied were safe, immunogenic, and efficacious against pertussis, whereas the efficacy of the whole-cell DTP vaccine was unexpectedly low.

AB - Background. Concern about both safety and efficacy has made the use of whole-cell pertussis vaccines controversial. In some European countries, including Italy, the rate of vaccination against pertussis is low. Methods. We conducted a double-blind trial in Italy in which infants were randomly assigned to vaccination at two, four, and six months of age with an acellular pertussis vaccine together with diphtheria and tetanus toxoids (DTP); a DTP vaccine containing whole-cell pertussis (manufactured by Connaught Laboratories); or diphtheria and tetanus toxoids without pertussis (DT). The acellular DTP vaccine was either one containing filamentous hemagglutinin, pertactin, and pertussis toxin inactivated with formalin and glutaraldehyde (SmithKline Beecham) or one with filamentous hemagglutinin, pertactin, and genetically detoxified pertussis toxin (Chiron Biocine). Pertussis was defined as 21 days or more of paroxysmal cough, with infection confirmed by culture or serologic testing. Results. The efficacy of each vaccine, given in three doses, against pertussis was determined for 14,751 children over an average of 17 months, with cases included in the analysis if cough began 30 days or more after the completion of immunization. For both of the acellular DTP vaccines, the efficacy was 84 percent (95 percent confidence intervals, 76 to 89 percent for SmithKline DTP and 76 to 90 percent for Biocine DTP), whereas the efficacy of the whole-cell DTP vaccine was only 36 percent (95 percent confidence interval, 14 to 52 percent). The antibody responses were greater to the acellular vaccines than to the whole-cell vaccine. Local and systemic adverse events were significantly more frequent after the administration of the whole-cell vaccine. For the acellular vaccines, the frequency of adverse events was similar to that in the control (DT) group. Conclusions. The two acellular DTP vaccines we studied were safe, immunogenic, and efficacious against pertussis, whereas the efficacy of the whole-cell DTP vaccine was unexpectedly low.

UR - http://www.scopus.com/inward/record.url?scp=13344286322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13344286322&partnerID=8YFLogxK

U2 - 10.1056/NEJM199602083340601

DO - 10.1056/NEJM199602083340601

M3 - Article

C2 - 8538704

AN - SCOPUS:13344286322

VL - 334

SP - 341

EP - 348

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 6

ER -